Update shared on27 Aug 2025
Fair value Increased 2.10%Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness.
Analyst Commentary
- Recent share price pullback seen as disconnected from underlying business strength.
- Organic profit growth forecasted through 2028 significantly outpaces sector peers.
- Robust fundamentals supporting long-term value creation.
- Analysts expect the company's earnings trajectory to remain resilient.
- Improved confidence in management’s ability to execute on growth initiatives.
What's in the News
- UCB raised its full-year 2025 revenue guidance to at least EUR 7 billion and core EPS to at least EUR 7.25.
- Phase 3 study of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met primary and key secondary endpoints, supporting efficacy and safety; long-term extension phase ongoing.
- UCB and Biogen reported positive Phase 3 PHOENYCS GO results for dapirolizumab pegol in systemic lupus erythematosus (SLE), with meaningful clinical improvements; a confirmatory Phase 3 trial is ongoing.
- UCB announced a major investment in a new U.S. biologics manufacturing facility, expected to create approximately 300 permanent jobs and deliver $5 billion in economic impact.
- Three-year data from Phase 3 trials showed sustained efficacy and safety of BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis; no new safety signals observed.
Valuation Changes
Summary of Valuation Changes for UCB
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from €219.56 to €223.17.
- The Consensus Revenue Growth forecasts for UCB remained effectively unchanged, moving only marginally from 10.9% per annum to 11.2% per annum.
- The Net Profit Margin for UCB remained effectively unchanged, moving only marginally from 21.49% to 21.87%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.